MR-2266
MR-2266 is a chemical compound that has been studied for its potential pharmacological effects, particularly in the context of opioid receptor antagonism. It is known to interact with various receptors in the central nervous system, which has implications for its use in research and potential therapeutic applications.
Pharmacology[edit | edit source]
MR-2266 is primarily recognized for its role as an opioid receptor antagonist. It binds to the mu-opioid receptor (MOR), kappa-opioid receptor (KOR), and delta-opioid receptor (DOR), inhibiting the effects of endogenous and exogenous opioids. This property makes it a compound of interest in the study of opioid addiction and overdose.
Mechanism of Action[edit | edit source]
The mechanism of action of MR-2266 involves competitive inhibition at the opioid receptors. By binding to these receptors, MR-2266 prevents opioid agonists from exerting their effects, which include analgesia, euphoria, and respiratory depression. This antagonistic action is crucial in reversing opioid overdose and in research settings to understand opioid receptor dynamics.
Research and Development[edit | edit source]
MR-2266 has been utilized in various preclinical studies to explore its effects on opioid receptor activity. Its ability to block opioid-induced responses has made it a valuable tool in neuroscience research, particularly in understanding the pathways involved in opioid addiction and withdrawal.
Potential Applications[edit | edit source]
While MR-2266 is primarily used in research, its properties suggest potential applications in clinical settings. These include:
- Opioid Overdose Treatment: As an opioid antagonist, MR-2266 could be used to reverse the effects of opioid overdose, similar to naloxone.
- Addiction Therapy: By blocking the rewarding effects of opioids, MR-2266 may aid in addiction treatment programs.
Safety and Efficacy[edit | edit source]
The safety profile of MR-2266 is still under investigation. As with any opioid antagonist, potential side effects may include withdrawal symptoms in individuals dependent on opioids. Further studies are needed to fully understand its efficacy and safety in both research and potential therapeutic contexts.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
